// App-Quantinova.ai

1875 : Subject Characteristics and Changes in Bone Mineral Density After Transitioning from Denosumab to Alendronate in the Denosumab Adherence Preference Satisfaction (DAPS) Study

Researchers

Presenter

  • Arkadi Chines

Principal Investigators

  • Patricia Clark

  • Peter R. Ebeling

  • Michael McClung

  • Yumie Rhee

  • Shuang Huang

  • Robert Kees Stad

  • Nick Freemantle

Medical Centers

  • The University of British Columbia, Vancouver, BC, Canada

  • Amgen Inc, Thousand Oaks, CA

  • Hospital Infantil de Mexico Federico Gómez and National University of Mexico, Mexico City, Mexico

  • Deakin University, Melbourne, Australia

  • Oregon Osteoporosis Center, Portland, OR

  • Yonsei University College of Medicine, Seoul, Korea

  • Amgen Inc., Rotkreuz, Zug, Switzerland

  • Kings College London, London, United Kingdom

Locations

  • Canada

  • United States

  • Mexico

  • Australia

  • Switzerland

  • United Kingdom

  • Republic of South Korea

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Bone Mineral Density

Drug/Treatment

  • Alendronate sodium

  • Denosumab

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

  • Open Label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved